Phase 2/3 study of lenalidomide in relapsed/refractory DLBCL

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Andrew Davies (University of Southampton, Southampton, UK) discusses the outcomes and clinical implications of a phase 2/3 multicent... Author: VJHemOnc Added: 04/30/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts